Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has completed its previously announced acquisition of Fermentas International Inc. With Fermentas' broad range of high-quality molecular and cellular biology research tools, including reagents, enzymes and kits, Thermo Fisher can offer a complete workflow for genomics research while building on its platform of PCR and qPCR tools and resources.
Fermentas has approximately 500 employees, is headquartered in Burlington, Ontario, and has principal operations in Vilnius, Lithuania. The company had full-year revenues of approximately CAD $57 million in 2009 (approximately USD $55 million). Fermentas will be integrated into Thermo Fisher Scientific's Analytical Technologies Segment.
Thermo Fisher Scientific collaborates with AstraZeneca and University of Nebraska Medical Center